Skip to main content

Cancer immunity and autoimmunity; two sides of the same coin (?)

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

The vast majority of research into the biology of autoimmune diseases has focussed on B-lymphocytes and CD4+ T helper cells, contrasting the limited efforts put into exploring the role of cytotoxic T lymphocytes (CTL). Although, the focus on CD8+ T cells in autoimmunity is increasing the target structures of these cells remain largely unknown. We describe CD8+ positive T cells recognizing a SS-56 derived peptide in the context of HLA-A2 in patients suffering from primary Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE). SS-56 is a recently described cellular target of autoantibody responses in these diseases. SS-56 specific T cells could readily be detected in circulation by ELISPOT and flow cytometry. Furthermore, in situ stainings revealed the presence of SS-56 specific CD8+ T cells among the infiltrating cells of SLE skin lesions. Remarkably, the SS-56 specific, CD8+ T cells cross react with an epitope from the previously described tumor antigen ML-IAP. In summary, this first description of a target for auto-reactive CTL in SS and SLE patients underscores the important role of CTL in autoimmune disorders. Furthermore, the crossreactivity against the auto-antigen SS-56 and the tumor-antigen ML-IAP confirms the proposed link between autoimmunity and anti-cancer cellular immune responses.

Document Type: Abstract

DOI: http://dx.doi.org/10.1111/j.1600-0463.2008.001165_9.x

Affiliations: 1: Department of Rheumatology, Copenhagen University Hospital, DK 2: Department of Dermatology, Würzburg University Hospital, Germany. Mail:, Email: ribaso01@heh.regionh.dk 3: Center for Cancer ImmuneTherapy (CCIT), Department of Hematology, University Hospital Herlev, DK

Publication date: May 1, 2008

mksg/apm/2008/00000116/00000005/art00019
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more